VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following ...

Little did he know this would be the beginning of his health seriously declining. The same year, Antony suddenly lost all ...